Tivic Health Systems Inc (TIVC)Healthcare | Medical Devices | Fremont, United States |
USD
|
Hot Take ↕ | June 7, 2026, 9:48 a.m. UTC
The investment case for this biotech pivot is currently nonexistent due to a catastrophic multi-year price collapse and deteriorating fundamentals. The stock has lost 99.88% of its value over the last three years, with the trailing twelve months showing a massive decline that suggests the market has thoroughly rejected the new strategic direction toward radiation and cancer treatments. Despite a technically impressive balance sheet with a current ratio of 20x, the company is burning significant cash, reporting negative free cash flow and negative operating cash flow, while earning negative returns on both assets and equity. The forward P/E is meaningless given the negative earnings, and the lack of any dividend history confirms this is a pure growth play that has failed to deliver. While recent headlines suggest a rebranding and strategic shift, the price action over the last two weeks shows continued weakness, trading well below the 50-day and 200-day averages, indicating that the market remains deeply skeptical of the turnaround potential. |
| Model | MAE |
|---|---|
| MSTL_104 ✓ | 0.194922 |
| MSTL_72_104 | 0.213109 |
| AutoTheta | 0.229560 |
| AutoETS | 0.233703 |
| MSTL | 0.238348 |
| MSTL_72 | 0.258266 |
| AutoARIMA | 0.273856 |
Forecast horizon: 60 days | Selected: MSTL_104
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 2.09 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.212 |
| Excess Kurtosis | -0.54 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 38.424 |
| Market Cap | 4,029,097 |
| Forward P/E | -0.06 |
| Beta | 1.84 |
| Website | https://tivichealth.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7927928 |
| Address1 | 47,685 Lakeview Blvd. |
| All Time High | 11,050.0 |
| All Time Low | 0.722 |
| Ask | 1.6 |
| Ask Size | 200 |
| Average Daily Volume10 Day | 350,240 |
| Average Volume | 265,971 |
| Average Volume10Days | 350,240 |
| Beta | 1.844 |
| Bid | 0.9936 |
| Bid Size | 200 |
| Book Value | 6.65 |
| City | Fremont |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Currency | USD |
| Current Price | 1.4 |
| Current Ratio | 20.133 |
| Date Short Interest | 1,776,211,200 |
| Day High | 1.4 |
| Day Low | 1.23 |
| Debt To Equity | 38.424 |
| Ebitda | -7,893,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.416 |
| Enterprise Value | -3,284,294 |
| Exchange | NCM |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 0.96438 |
| Fifty Two Week High | 5.6 |
| Fifty Two Week Low | 0.722 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,636,641,000 |
| Float Shares | 2,516,113 |
| Forward Eps | -24.0 |
| Forward P E | -0.058333334 |
| Free Cashflow | -4,292,500 |
| Full Time Employees | 52 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Held Percent Insiders | 0.01461 |
| Held Percent Institutions | 0.080129996 |
| Implied Shares Outstanding | 2,877,927 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,741,305,600 |
| Last Split Factor | 1:17 |
| Long Business Summary | Valion Bio, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas. |
| Long Name | Tivic Health Systems Inc |
| Market Cap | 4,029,097 |
| Max Age | 86,400 |
| Message Board Id | finmb_435306147 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -7,993,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,936,818 |
| Open | 1.3 |
| Operating Cashflow | -6,999,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 888 276 6888 |
| Previous Close | 0.0 |
| Price Hint | 4 |
| Price To Book | 0.2105263 |
| Profit Margins | 0.0 |
| Quick Ratio | 19.574 |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Regular Market Day High | 1.4 |
| Regular Market Day Low | 1.23 |
| Regular Market Open | 1.3 |
| Regular Market Previous Close | 0.0 |
| Regular Market Volume | 263,294 |
| Return On Assets | -0.28687 |
| Return On Equity | -0.82692003 |
| Sand P52 Week Change | 0.23177934 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,877,926 |
| Shares Percent Shares Out | 0.0222 |
| Shares Short | 63,926 |
| Shares Short Previous Month Date | 1,773,360,000 |
| Shares Short Prior Month | 169,146 |
| Short Name | Tivic Health Systems, Inc. |
| Short Percent Of Float | 0.0225 |
| Short Ratio | 0.78 |
| State | CA |
| Symbol | TIVC |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 12,645,000 |
| Total Cash Per Share | 4.394 |
| Total Debt | 6,454,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | -6.92 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 2.039815 |
| Underlying Symbol | TIVC |
| Uuid | ab2ce24b-9f4c-3441-991c-7bbc4d382290 |
| Volume | 263,294 |
| Website | https://tivichealth.com |
| Zip | 94,538 |